Net profit of Suven Pharmaceuticals rose 3.33% to Rs 82.21 crore in the quarter ended September 2024 as against Rs 79.56 crore during the previous quarter ended September 2023. Sales rose 11.54% to Rs 257.72 crore in the quarter ended September 2024 as against Rs 231.05 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales257.72231.05 12 OPM %40.3642.40 - PBDT116.46117.30 -1 PBT99.50105.41 -6 NP82.2179.56 3 Powered by Capital Market - Live News

Suven Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 28 November 2024 .Powered by Capital Market - Live News

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live News

Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effective 20 September 2024, as Vaidheesh Annaswamy decides to transition from the Board and becomes the Vice-Chair of Suven`s Advisory council.Powered by Capital Market - Live News

The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the following:Vaidheesh Annaswamy (DIN: 01444303) has decided to step down from his role as Executive Chairperson and Director of the Company, effective from close of business hours on 19 September 2024.Approved the appointment of Vivek Sharma (DIN: 08559495) as an Additional Director and Executive Chairman of the Company, as recommended by the Nomination and Remuneration Committee, for a period of five years with effect from 20 September 2024, subject to approval of the shareholders through postal ballot process. Powered by Capital Market - Live News